Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

NAFLD risk, remission influenced by lifestyle

29 Jan 2020

Lifestyle factors, such as weight gain, smoking and exercise, appear to affect the development and remission of nonalcoholic fatty liver disease (NAFLD), reports a recent study.

Researchers performed a longitudinal cohort study including 1,421 participants (mean age, 53.0±11.9 years; 50.0 percent male) whose only cause of liver disease was NAFLD. At baseline, 34.1 percent (n=484) were diagnosed with NAFLD. Participants were followed for a mean of 4.6±2.8 years, during which time they had a mean of 4.8±2.7 checkup visits each.

Over the follow-up period, 11.1 percent (n=104) of the 937 patients who were free of NAFLD at baseline developed the disease at a rate of 2.4 percent per year. On the other hand, 26.2 percent of those with NAFLD at baseline achieved remission.

Multivariate analysis found that males were at a significantly greater risk of developing NAFLD (adjusted odds ratio [OR], 2.07, 95 percent confidence interval [CI], 1.35–3.21). The same was true for a longer follow-up period (adjusted OR, 1.11, 1.03–1.20), having dyslipidaemia (adjusted OR, 2.39, 95 percent CI, 1.25–4.56) and smoking cessation (adjusted OR, 2.86, 95 percent CI, 1.24–6.62).

In the study, participants who quit smoking were more likely to demonstrate large gains in weight (p<0.001) which, in turn, correlated with a stronger risk of NAFLD (p<0.001). Failing to lose weight was likewise a significant risk factor (adjusted OR, 0.30, 0.18–0.50). In contrast, weight loss significantly increased the chances of NAFLD remission (adjusted OR, 2.83, 95 percent CI, 1.80–4.44).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.